# Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi).

> PubMed lists PMID 32561160 in Journal of diabetes and its complications as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-31 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32561160-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32561160-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-32561160-lixisenatide-v1.json
- Content SHA-256: `8e7fe43a29166ec389bab09ff8a65182483713bd37c18d42d5d856f5e348e9dd`

## Claims and source pins

### Headline

Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi). ([`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`](#source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd))

### Summary

PubMed lists PMID 32561160 in Journal of diabetes and its complications as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-31 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`](#source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd))

### Paragraph 1

PubMed lists PMID 32561160 in Journal of diabetes and its complications as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-31 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`](#source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`](#source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd))

## Sources

<a id="source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd"></a>
- **Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi). · retained source version 1:2026-01-27:current:0e222d6c92cd228a89a1e8d098f48b6fda3ead24587cb3807fd950cf1f7afb6c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32561160/) (`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi)." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-32561160-lixisenatide-v1.json SHA-256: 8e7fe43a29166ec389bab09ff8a65182483713bd37c18d42d5d856f5e348e9dd.